Irit Arbel - 26 Feb 2026 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Director
Issuer ticker: BCLI
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 17:00:26 UTC
Prior SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Irit Arbel

Key filing fact

Irit Arbel filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 29 May 2026.

Key facts

This page summarizes Irit Arbel's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 May 2026, 17:00.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001245607 Primary reporting owner

ARBEL IRIT

Relationship: Director
Address: C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FLOOR, NEW YORK
Signature: /s/ Irit Arbel
Signature date: 29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value
Shares: +120,000
Change %: +292%
Price: $0.000000^*
Shares after: 161,054
Date: 26 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.